Physician profile
Ying Hu
NPI 1134370018
$18,851.56
in general payments reported to CMS, 2019-2025
51 companies · $2,451 in 2025
The $2,451 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,680 · 2020: $2,150 · 2021: $1,824 · 2022: $2,621 · 2023: $2,509 · 2024: $3,615 · 2025: $2,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,595 · Travel and Lodging: $901 · Gift: $59.40 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,595.15 |
| Travel and Lodging | $900.81 |
| Gift | $59.40 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,148.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,480.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $1,900.96 | 2021-2025 | Minimed 780g |
| Amgen INC. | $1,826.63 | 2019-2025 | Evenity, Prolia, Prolia |
| Sanofi-Aventis U.S. LLC | $1,044.63 | 2019-2025 | |
| Dexcom, INC. | $959.34 | 2020-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $829.65 | 2019-2023 | Steglatro |
| Abbvie INC. | $762.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $598.14 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $588.67 | 2019-2021 | |
| Amarin Pharma, INC. | $450.25 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $447.55 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $387.07 | 2020-2025 | Afrezza |
| Radius Health, INC. | $352.76 | 2019-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $301.85 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.